Could a medicine being studied for metabolic health also help someone reduce heavy drinking? That is a question I want to follow, because more useful options could matter enormously.
But “another possible option” is different from “a cure for addiction”. The person, their circumstances and their support still matter.
What happened in RECLAIM?
On 28 July 2026, Altimmune announced results from a 24-week trial involving 100 people with alcohol use disorder and overweight or obesity. They were assigned by chance to pemvidutide or placebo. Pemvidutide is investigational and acts on two hormone pathways, glucagon and GLP-1. [1]
The company reported an average reduction of 4.20 heavy-drinking days per week with pemvidutide, compared with 2.75 with placebo. The additional reduction compared with placebo was therefore 1.45 days a week. These are adjusted group averages, not a prediction for an individual. [1]
Fewer heavy-drinking days is not the same as no drinking. It also does not tell us how someone felt or what support they needed along the way.
How manageable was treatment?
Nausea was reported by 44% of the pemvidutide group and 24% of the placebo group. Overall, 20% and 22% stopped treatment respectively. But when the company counted people who stopped because of events attributed to the study medicine, the figures were 10% and 0%. [1]
Those are different questions. Similar overall stopping rates do not necessarily mean two treatments were equally easy to live with.
There were two serious adverse events with pemvidutide and one with placebo. A case of low blood sodium in the pemvidutide group was considered possibly related to treatment. [1]
What would I want to know next?
This is a company announcement, not a complete peer-reviewed report. Altimmune has a commercial interest. Fuller reporting matters for understanding missing results, side effects and why people stopped.
The trial does not establish a women-specific benefit, a cure for addiction or the same result outside this group. Twenty-four weeks cannot tell us what happens over years or after treatment ends.
It is also a different medicine from semaglutide, the active ingredient in Ozempic, covered in our earlier recovery note. We cannot simply transfer one medicine’s findings to another.
The person still comes first
Healthdirect describes help including counselling, behavioural treatment and other clinical support. [2] This trial does not show that those things can be set aside.
I am interested in whether new research can add something useful to care. Recovery should never be reduced to an injection or a number in a trial.
You can ask for help now
If you may be alcohol-dependent, get medical advice before stopping suddenly; withdrawal can be unsafe. [3]
For confidential support in Australia, call the National Alcohol and Other Drug Hotline on 1800 250 015. [4]
Read the original sources
- Altimmune: RECLAIM Phase 2 results announcement ↗28 July 2026 · Manufacturer-reported initial findings, including efficacy and adverse-event tables. Not a full peer-reviewed trial report.
- Healthdirect: alcohol dependence and treatment support ↗Australian patient guidance · Included for established support options, not as evidence for pemvidutide.
- Healthdirect: withdrawal and medical support ↗Patient guidance · Planning withdrawal with a clinician.
- Australian Government: National Alcohol and Other Drug Hotline ↗Free, confidential information and support.